(Q54649694)

English

Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer

scientific article published on September 16, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer (English)

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

author name string

Xi-ru Li

1

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

Mei Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

Yan-jun Zhang

3

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

Jian-dong Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

Yi-qiong Zheng

5

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

Jie Li

6

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

Bing Ma

7

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

Xin Song

8

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20844986

14 July 2024

publication date

16 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

full work available at URL

http://link.springer.com/content/pdf/10.1007/s12032-010-9676-z.pdf

Portable Document Format

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

http://link.springer.com/article/10.1007/s12032-010-9676-z/fulltext.html

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

http://link.springer.com/content/pdf/10.1007/s12032-010-9676-z

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

28 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

S31-8

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Signal transduction pathways of taxanes-induced apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Assessment of response to therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Predictive markers of response to neoadjuvant chemotherapy in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Utilizing prognostic and predictive factors in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Apoptosis induced by neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9676-Z

21 January 2018

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

3

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

4

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

Cancer chemotherapy and biological response modifiers

11

11

45

author name string

BK Sinha

publication date

1990

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

18

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

21

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer

28

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers

30

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

Prediction of response to primary chemotherapy for operable breast cancer

33

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

Protein Markers in Colorectal Cancer

37

1 reference

10.1007/S12032-010-9676-Z

https://api.crossref.org/works/10.1007/S12032-010-9676-Z

14 July 2024

Identifiers

10.1007/S12032-010-9676-Z

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20844986

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54649694&oldid=2212550088"